Contraception
Volume 82, Issue 1 , Pages 64-71 , July 2010

Safety of contraceptive methods for women with rheumatoid arthritis: a systematic review

Received 1 February 2010 ,Accepted 2 February 2010.

References 

  1. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65:1608–1612
  2. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States, Part I. Arthritis Rheum. 2008;58:15–25
  3. Cutolo M, Wilder RL. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum Dis Clin North Am. 2000;26:825–839
  4. Cutolo M. Sex hormone adjuvant therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2000;26:881–895
  5. Ostensen M, Villiger PM. The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29:185–191
  6. Hazes JM, Van ZD. Oral contraception and its possible protection against rheumatoid arthritis. Ann Rheum Dis. 1991;50:72–74
  7. Pladevall-Vila M, Delclos GL, Varas C, Guyer H, Brugues-Tarradellas J, Anglada-Arisa A. Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol. 1996;144:1–14
  8. Browne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2008;112:667–669
  9. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women?. BJOG. 2001;108:784–790
  10. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144–148
  11. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed.. Geneva: World Health Organization; 2004;
  12. World Health Organization . Medical eligibility criteria for contraceptive use, 2008 update Geneva, Switzerland. World Health Organization; 2008;[cited 2009 Jan 22]
  13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324
  14. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35
  15. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med. 2007;147:871–875
  16. Demers R, Blais JA, Pretty H. Rheumatoid arthritis treated by norethynodrel associated with mestranol: clinical aspects and laboratory tests. Can Med Assoc J. 1966;95:350–354
  17. Drossaers-Bakker KW, Zwinderman AH, Van ZD, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002;61:405–408
  18. Gilbert M, Rotstein J, Cunningham C, Estrin I, Davidson A, Pincus G. Norethynodrel with mestranol in treatment of rheumatoid arthritis. JAMA. 1964;190:235
  19. Gill D. Rheumatic complaints of women using anti-ovulatory drugs. An evaluation. J Chronic Dis. 1968;21:435–444
  20. Hazes JM, Dijkmans BA, Vandenbroucke JP, Cats A. Oral contraceptive treatment for rheumatoid arthritis: an open study in 10 female patients. Br J Rheumatol. 1989;28((Suppl) 1):28–30
  21. Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol. 1983;12:69–72
  22. Vignos PJ, Dorfman RI. Effect of large doses of progesterone in rheumatoid arthritis. Am J Med Sci. 1951;222:29–34
  23. Bijlsma JW, Huber-Bruning O, Thijssen JH. Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis. Ann Rheum Dis. 1987;46:777–779
  24. Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:273–281
  25. van Vollenhoven RF, McGuire JL. Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases?. Cleve Clin J Med. 1994;61:276–284
  26. Neinstein LS, Katz B. Connective tissue diseases, arthritis require special patient counseling. Contracept Technol Update. 1985;6:100–102
  27. Lautenbach GL, Petri M. Women's health. Rheum Dis Clin North Am. 1999;25:539–565
  28. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–2293
  29. van Albada-Kuipers GA, Linthorst J, Peeters EA, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum. 1988;31:667–671
  30. Vandenbroucke JP, Kaaks R, Valkenburg HA, et al. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum. 1987;30:810–813
  31. Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Arch Intern Med. 2004;164:603–614
  32. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol. 2003;15:469–475
  33. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487

☆ The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S0010-7824(10)00047-8

doi: 10.1016/j.contraception.2010.02.003

Contraception
Volume 82, Issue 1 , Pages 64-71 , July 2010

Article Tools